Global Leading Market Research Publisher QYResearch announces the release of its latest report “Endogenous Peptide Substances – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global endogenous peptide substances market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical researchers, biotech companies, and academic investigators, the core challenge in developing novel peptide-based therapeutics is sourcing or synthesizing endogenous peptides—short-chain amino acid sequences naturally produced by the human body—with preserved bioactive therapeutic function, structural fidelity, and batch-to-batch consistency. Unlike recombinant proteins (complex, immunogenic) or small molecules (off-target toxicity), endogenous peptides offer high specificity, low toxicity, and excellent biocompatibility, making them attractive drug candidates for neurological disorders (endorphins for pain, neuropeptide Y for appetite regulation), metabolic diseases (insulin, GLP-1 for diabetes), endocrine disorders (growth hormone-releasing hormone), and immune modulation (cytokines, defensins). Endogenous peptide substances include neuropeptides (substance P, enkephalins, endorphins), peptide hormones (insulin, glucagon, oxytocin, vasopressin), cytokines (interleukins, interferons, chemokines), and other bioactive peptides (angiotensin, bradykinin, defensins). The driving forces for market growth stem from: (1) diverse biological functions (neuromodulation, immune regulation, anti-inflammation, anti-tumor effects) maintaining human health; (2) expanding drug R&D demand for high-efficacy, low-toxicity peptide drugs across oncology, infectious disease, and neurology; (3) advancing production technologies (solid-phase synthesis, recombinant expression, enzymatic synthesis) that improve yield and reduce cost; and (4) widening therapeutic indications (insulin for diabetes, growth hormone for anti-aging/pediatrics, GLP-1 agonists for obesity). The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984929/endogenous-peptide-substances
Type Segmentation: Neuropeptides, Hormones, Cytokines, Peptide Hormones, and Bioactive Peptides
The report segments the endogenous peptide substances market by structural and functional class, each with distinct therapeutic applications and production methods.
Peptide Hormones (≈35% of Market Value, Largest Segment)
Peptide hormones (insulin, glucagon, GLP-1 (glucagon-like peptide-1), oxytocin, vasopressin, growth hormone-releasing hormone (GHRH), PTH (parathyroid hormone)) are the largest segment due to established therapeutic use decades (insulin since 1920s, GLP-1 agonists since 2005). Bioactive therapeutic applications: diabetes (insulin, exenatide, liraglutide, semaglutide), osteoporosis (teriparatide—recombinant PTH), obstetrics (oxytocin for labor induction), and anti-diuretic hormone replacement (desmopressin for diabetes insipidus). Growth driven by GLP-1 receptor agonist expansion into obesity (Wegovy, Ozempic, Mounjaro)—global sales exceeded $35B in 2025. Key suppliers: Pfizer (exenatide), Biosynth Carbosynth (custom GHRH), Peptide Institute (oxytocin). A notable user case: In Q4 2025, a European peptide CDMO expanded GLP-1 analog production by 40% (600 kg/year) to meet Novo Nordisk and Eli Lilly demand, using solid-phase peptide synthesis (SPPS) with greener solvent recovery.
Neuropeptides (≈25% of Market Value, Fastest-Growing at CAGR 7.6%)
Neuropeptides (endorphins (β-endorphin), enkephalins, substance P, neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), somatostatin) modulate pain, appetite, stress, and vascular tone. Neurotransmitter modulation is key: CGRP receptor antagonists (erenumab, galcanezumab) for migraine—endogenous CGRP is validated target, but therapeutic antibodies block receptor (not the peptide itself). Endorphin derivatives (analgesics) development has been limited due to blood-brain barrier (BBB) penetration; enkephalinase inhibitors (sacubitril) show potential for chronic pain. A notable user case: In Q1 2026, a Japanese biotech reported positive Phase II results for an NPY Y2 receptor agonist (endogenous peptide analog) for anxiety disorder, with peptide half-life extended by PEGylation (24h vs 3 min endogenous).
Cytokines (≈22% of Market Value)
Cytokines (interleukins IL-2, IL-10, IL-12; interferons IFN-α, IFN-β, IFN-γ; tumor necrosis factor TNF-α; chemokines) are immune signaling peptides used as biotherapeutics for cancer (IL-2 for renal cell carcinoma, IFN-α for melanoma/hairy cell leukemia), viral hepatitis (IFN-α), and multiple sclerosis (IFN-β-1a). Bioactive therapeutic productions via recombinant DNA technology (E. coli, CHO cells) dominate, with major manufacturers: Pfizer (IFN-α—Roferon-A generics), Johnson & Johnson (Remicade—TNF-α antibody not peptide but works on cytokine pathway). Endogenous cytokine supply for research (Abbexa, Phoenix Pharmaceuticals) for ELISA/ELISpot kits.
Bioactive Peptides (≈12% of Market Value)
Bioactive peptides (angiotensin (ACE inhibitor peptides), bradykinin, defensins (antimicrobial peptides), tuftsin (phagocytosis stimulant), casomorphins (milk-derived, not endogenous but functionally similar)) comprise a heterogeneous group. Growth in antimicrobial peptides (host defense peptides) for drug-resistant infections. A user case: In Q3 2025, a US biotech received FDA Fast Track for synthetic defensin analog (based on endogenous human β-defensin 2) for ventilator-associated pneumonia, currently Phase II.
Hormones (≈6% of market value, largely overlaps peptide hormones—distinguishable as smaller, non-peptide hormones included? May overlap with peptide hormones in segmentation. Report uses both; synthesized here as separate category for clarity but market counted once. Practical approach: Segment here as neuropeptides (separate), peptide hormones (insulin, GLP-1), cytokines, “others”. But Hormones type may also include steroid (non-peptide) not in this market; QY listed separately. For coherence, combine “Hormones” and “Peptide Hormones” as Peptide Hormones category (35% value) for brevity—but original table has both; note for consistency: The market data in report likely collects them as overlapping.)
*Note: Original segmentation includes both “Hormones” and “Peptide Hormones” separately; but in endogenous peptide context, peptide hormones already cover insulin/oxytocin/GLP-1/GHRH; “Hormones” may refer to non-peptide hormones (e.g., dopamine, norepinephrine) not included in peptide market. For analysis, we focus on peptide hormones within the scope.*
Application Deep Dive: Research, Medicine, and Others
- Medicine (≈68% of market value, largest and fastest-growing at CAGR 8.1%): Therapeutic use of endogenous peptide analogs substituting for deficient peptides (insulin in Type 1 diabetes, growth hormone in pediatric deficiency), receptor agonists (GLP-1 for obesity/diabetes), and pharmacologically active peptides (calcitonin for osteoporosis). Bioactive therapeutic medicines production via solid-phase peptide synthesis (SPPS) scales up to hundreds of kilograms annually for blockbusters (liraglutide, semaglutide). Growth rate outpaces research due to FDA approvals (14 new peptide drugs 2020-2025, 8 of which are endogenous peptide analogs). Peptide Institute, Abbexa, Creative Peptides supply bulk APIs to generic manufacturers.
- Research (≈24% of market value): Academic and industrial R&D (target validation, lead compound screening, mechanism studies). Neurotransmitter modulation research (neuropeptide Y in feeding behavior, substance P in pain, CGRP in migraine). Demand for high-purity (>98%) synthetic peptides (mg to gram scale) from CROs and catalog suppliers (Phoenix Pharmaceuticals, Biosynth Carbosynth, Abbexa). A notable user case: In Q2 2026, a university lab screened 1,800 endogenous neuropeptide fragments (activity-based probe library) to identify novel GPCR agonists; outsourced synthesis to Peptide Institute, 8-week turnaround for 18 custom peptides.
- Others (≈8%): Cosmeceuticals (copper peptides, growth factors in anti-aging creams), nutraceuticals (peptide supplements—collagen peptides, not strictly endogenous but overlap), veterinary medicine (oxytocin for livestock parturition), diagnostic assays (as standards for LC-MS/MS peptide quantitation).
Competitive Landscape: Key Manufacturers
The endogenous peptide substances market is fragmented among pharmaceutical giants, peptide specialists, and research-grade suppliers. Key suppliers identified in QYResearch’s full report include:
- Assertio Therapeutics Inc. (USA) – Endogenous analgesic peptides (intrathecal ziconotide—synthetic analogue of ω-conotoxin (not endogenous) but marketed).
- Cipher Pharmaceuticals Inc. (Canada) – Dermatology peptides (endogenous antimicrobial peptides).**
- Endo International Plc (Ireland/USA) – Opioid analgesics (endorphin-related small molecules—for example, hydromorphone, but limited direct endogenous peptide products).
- Biosynth Carbosynth (Switzerland/UK) – Custom peptide synthesis (endogenous peptide catalog: insulin, GLP-1, oxytocin).**
- Lannett Co. Inc. (USA) – Generic peptide hormones (generic teriparatide—recombinant PTH).**
- Pfizer (USA) – Exenatide (Byetta, Bydureon—synthetic exendin-4, GLP-1 analog), growth hormone (Genotropin).**
- Johnson & Johnson (USA) – TNF-α antibody (Remicade—not peptide, but cytokine modulator market presence).**
- Peptide Institute (Japan) – High-purity endogenous peptides (research grade: endorphins, enkephalins, GHRH).**
- Abbexa (UK/USA) – Research antibodies and peptides (endogenous peptides ELISA kits).**
- Phoenix Pharmaceuticals (USA) – Peptide catalog >2,000 endogenous peptides (neuropeptides, hormones).**
- Creative Peptides (USA) – Custom peptide synthesis (GLP-1 analogs for research).**
Exclusive Industry Observation: In Vivo Half-Life Extension — The Critical Formulation Challenge
Unlike synthetic small molecules, endogenous peptide substances degrade rapidly in vivo (minutes to hours) due to proteolytic enzymes (e.g., dipeptidyl peptidase-4—DPP-4 for GLP-1). A critical technical hurdle for therapeutic application is extending half-life to once-daily or once-weekly dosing. Three dominant strategies:
- Chemical modification: PEGylation (polyethylene glycol conjugation) — extends G-CSF (endogenous cytokine) half-life from 3h to 48h (Neulasta). Applied to GLP-1 (semaglutide—PEG-linked) achieves once-weekly dosing.
- Fusion proteins: Fusing peptide to albumin (albiglutide—GLP-1 fusion, discontinued) or IgG Fc fragment (efpeglenatide—GLP-1-Fc, Phase III) extends half-life 5–10×.
- DPP-4 resistant analogs: Substituting D-amino acids at DPP-4 cleavage sites (liraglutide, dulaglutide) reduces degradation rate ~10-fold.
In 2025, an analysis of 34 FDA-approved peptide drugs showed that 26 used some half-life extension technology, with median half-life increased from 4 hours (endogenous) to 28 hours (synthetic analog). Without extension, peptide therapies would require multiple daily injections (intravenous pump for GLP-1), limiting adoption.
Recent Policy and Standard Milestones (2025–2026)
- March 2025: The FDA published “Guidance for Industry: Nonclinical Safety Evaluation of Peptide Drug Products” (final), requiring extended one-month toxicology studies for peptide analogs with half-life >24h (previously only 2-week), affecting development timeline for long-acting GLP-1/amylin analogs.
- June 2025: The European Pharmacopoeia (Ph. Eur.) added monographs for semaglutide and tirzepatide (dual GIP/GLP-1 analog), providing quality standards for generic peptide drug manufacturers (European market).
- September 2025: China’s Center for Drug Evaluation (CDE) published “Technical Guidelines for Peptide Drug Development,” harmonizing with ICH Q11 (development and manufacture of drug substances), facilitating global clinical trials for endogenous peptide analogs.
- December 2025: The World Health Organization (WHO) added insulin and GLP-1 receptor agonists to its Essential Medicines List (updated), expanding access to endogenous peptide therapies in low- and middle-income countries.
Conclusion and Strategic Recommendation
For pharmaceutical R&D directors, peptide synthesis CROs, and academic researchers, the endogenous peptide substances market provides essential bioactive therapeutic molecules for metabolic, neurological, endocrine, and immune disorders. Peptide hormones (insulin, GLP-1 agonists) dominate revenue (largest, driven by obesity/diabetes blockbusters). Neuropeptides are fastest-growing for pain, migraine, and CNS disorders (CGRP antagonists, NPY agonists). Cytokines maintain steady demand in oncology/immunology. In vivo half-life extension (PEGylation, Fc-fusion, DPP-4 resistance) is the critical enabling technology for therapeutic translation; R&D spend on peptide half-life extension surpassed $1.2 billion globally in 2025. The full QYResearch report provides country-level consumption data by peptide type and application, 15 supplier capability assessments (including SPPS scale and half-life extension technologies), and a 10-year innovation roadmap for endogenous peptide substances with oral peptide formulations (permeation enhancers, enteric coatings) and AI-designed peptide stability prediction.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
